Research Set to Expand as Federal Government Considers Rescheduling Cannabis from Schedule I to Schedule III with Phil Johnston Johnston Associates TRANSCRIPT
Release Date: 05/13/2024
Driving Innovation in Cell Therapy Manufacturing with Ryan Clarke Syntax Bio TRANSCRIPT
Empowered Patient Podcast
Ryan Clarke, Co-Founder and CTO of Syntax Bio, is focused on solving manufacturing challenges in producing stem cell-derived therapies, specifically the process of stem cell differentiation. The Cellgorithm platform was designed to make differentiation an engineering problem by using a modified form of CRISPR to turn genes on and off in a specific, controlled sequence, reducing processing time from months to days and resulting in cost savings. One goal is to use AI and machine learning to build models capable of predicting optimal gene regulation sequences accelerating the discovery of...
info_outline
Driving Innovation in Cell Therapy Manufacturing with Ryan Clarke Syntax Bio
Empowered Patient Podcast
Ryan Clarke, Co-Founder and CTO of Syntax Bio, is focused on solving manufacturing challenges in producing stem cell-derived therapies, specifically the process of stem cell differentiation. The Cellgorithm platform was designed to make differentiation an engineering problem by using a modified form of CRISPR to turn genes on and off in a specific, controlled sequence, reducing processing time from months to days and resulting in cost savings. One goal is to use AI and machine learning to build models capable of predicting optimal gene regulation sequences accelerating the discovery of...
info_outline
Origins and Future of Medical Imaging with Dr. David Sodickson Function Health TRANSCRIPT
Empowered Patient Podcast
Dr. Daniel Sodickson is Chief Medical Scientist at Function Health and author of the new book, The Future of Seeing: How Imaging Is Changing Our World. Building on the drive to improve medical imaging, AI and neural networks are now reshaping image interpretation and how and what data are collected. This approach produces high-quality results with minimal additional data and is inspiring innovative scanning techniques and equipment design. The future of medical imaging is the everywhere scanner, enhancing a single-shot session with a large hospital machine with continuous health...
info_outline
Origins and Future of Medical Imaging with Dr. David Sodickson Function Health
Empowered Patient Podcast
Dr. Daniel Sodickson is Chief Medical Scientist at Function Health and author of the new book, The Future of Seeing: How Imaging Is Changing Our World. Building on the drive to improve medical imaging, AI and neural networks are now reshaping image interpretation and how and what data are collected. This approach produces high-quality results with minimal additional data and is inspiring innovative scanning techniques and equipment design. The future of medical imaging is the everywhere scanner, enhancing a single-shot session with a large hospital machine with continuous health...
info_outline
Stem Cell Therapy Aims to Rebuild Brain Circuits in Parkinson’s Patients with Dr. Howard Federoff Kenai Therapeutics TRANSCRIPT
Empowered Patient Podcast
Dr. Howard Federoff, Scientific Co-Founder, Chief Medical Officer, and Executive Vice President of Corporate Medicine and Science at Kenai Therapeutics, is developing a cell therapy for Parkinson's disease that involves transplanting IPSCs into the brain to replace lost dopamine neurons. The goal is not to cure the underlying cause of the disease, but to restore motor function and reverse the disease's progression. Initial clinical focus was on patients with moderate to moderate-severe idiopathic Parkinson's, showing efficacy and safety, leading to expanding the study to include...
info_outline
Stem Cell Therapy Aims to Rebuild Brain Circuits in Parkinson’s Patients with Dr. Howard Federoff Kenai Therapeutics
Empowered Patient Podcast
Dr. Howard Federoff, Scientific Co-Founder, Chief Medical Officer, and Executive Vice President of Corporate Medicine and Science at Kenai Therapeutics, is developing a cell therapy for Parkinson's disease that involves transplanting IPSCs into the brain to replace lost dopamine neurons. The goal is not to cure the underlying cause of the disease, but to restore motor function and reverse the disease's progression. Initial clinical focus was on patients with moderate to moderate-severe idiopathic Parkinson's, showing efficacy and safety, leading to expanding the study to include...
info_outline
Transforming MRI Data to Identify Biomarkers for Diagnosing and Treating Back Pain with Brent Ness Aclarion TRANSCRIPT
Empowered Patient Podcast
Brent Ness, CEO and President of Aclarion, highlights the challenges of diagnosing and treating chronic lower back pain, a leading driver of healthcare costs and opioid addiction. Traditional MRI and CT imaging do not reveal the biochemical source of pain within spinal discs, leading to misdiagnosis and unsuccessful treatment. The Aclarion technology uses MR spectroscopy to measure pain-causing biomarkers and, through a cloud-based, AI-powered SaaS model, analyzes the raw data and sends the physician a report within minutes. Brent explains, "The diagnosis and accurate treatment planning...
info_outline
Transforming MRI Data to Identify Biomarkers for Diagnosing and Treating Back Pain with Brent Ness Aclarion
Empowered Patient Podcast
Brent Ness, CEO and President of Aclarion, highlights the challenges of diagnosing and treating chronic lower back pain, a leading driver of healthcare costs and opioid addiction. Traditional MRI and CT imaging do not reveal the biochemical source of pain within spinal discs, leading to misdiagnosis and unsuccessful treatment. The Aclarion technology uses MR spectroscopy to measure pain-causing biomarkers and, through a cloud-based, AI-powered SaaS model, analyzes the raw data and sends the physician a report within minutes. Brent explains, "The diagnosis and accurate treatment planning...
info_outline
First Non-Steroidal MRA Drug Approved for Heart Failure with Dr. Alanna Morris-Simon Bayer TRANSCRIPT
Empowered Patient Podcast
Dr. Alanna Morris-Simon, Senior Medical Director for US Medical Affairs at Bayer, describes the symptoms and diagnostics used to classify heart failure and the key at-risk populations for this condition. The rapidly evolving landscape of heart failure treatments now includes the Bayer drug KERENDIA, a non-steroidal MRA approved to reduce cardiovascular death and heart failure in adults with an ejection fraction of 40% or more. This drug is part of an emerging trend to treat multiple related conditions simultaneously and could prevent the onset of heart failure and treat established...
info_outline
First Non-Steroidal MRA Drug Approved for Heart Failure with Dr. Alanna Morris-Simon Bayer
Empowered Patient Podcast
Dr. Alanna Morris-Simon, Senior Medical Director for US Medical Affairs at Bayer, describes the symptoms and diagnostics used to classify heart failure and the key at-risk populations for this condition. The rapidly evolving landscape of heart failure treatments now includes the Bayer drug KERENDIA, a non-steroidal MRA approved to reduce cardiovascular death and heart failure in adults with an ejection fraction of 40% or more. This drug is part of an emerging trend to treat multiple related conditions simultaneously and could prevent the onset of heart failure and treat established...
info_outlinePhil Johnston, President and CEO of Johnston Associates, and an advisor to EO Care, the market leader in providing clinically-guided cannabis use. Phil discusses the potential for research from the reclassification of cannabis from a Schedule I drug to a Schedule III drug. With current Federal restrictions on cannabis, research has not been conducted on the potential therapeutic use for pain relief, depression, PTSD, and other conditions. With a change in classification, researchers can develop protocols, test different cannabis strains, run clinical trials, and determine dosage and form for therapies.
Phil explains, "So changing the Schedule from I to III is a game-changer because it's going to allow for research in the cannabis area in terms of dosage, what's the appropriate dosage, what kind of marijuana should be used for whatever ails you. There's a particular emphasis, of course, on pain relief and sleeplessness and depression. It appears that cannabis can have a very serious positive impact on those maladies, but we need much more research, and that's where we come in. That's what we're trying to focus on with EO Care."
"If you talk to any MD in the country, they'll tell you that they didn't learn anything about cannabis in medical school, and that was because of the Federal ban. And so there hasn't been a lot of research done. It's anecdotal at this point, such as my wife's situation, and what we need is for the Federal Government and the states to lead the way to make sure that there's funding for research and that medical schools are including that in their curricula. The research will involve what normally is involved with drugs, which is trials to determine exactly what the best treatments would be."
"Dosing is very important to figure out how much of it one needs, given whatever the specific problem is. And none of that research has been done in this country yet. Now, we're doing a sweep of international studies. It turns out that Canada, which legalized this a long time ago, has done trials and has some research, which we can adapt. However, that work has to be done, and it has to be done within medical institutions in the United States as well."
#MedicalCannabisAccessibility #MedicalCannabisClinicalResearch #MedicalCannabisCancerPatients #CannabisRescheduling #FutureofMedicalCannabis
